SAP SE

  • WKN: 716460
  • ISIN: DE0007164600
  • Land: Deutschland

Nachricht vom 14.09.2010 | 11:05

SAP AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


SAP AG  / Release of an announcement according to Article 21, Section 1
of the WpHG [the German Securities Trading Act] (share)

14.09.2010 11:05

Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

On September 10, 2010 BlackRock, Inc., New York, USA, BlackRock Financial Management, Inc., New York, USA, and BlackRock Holdco 2, Inc., Wilmington, Delaware, USA, informed us pursuant to section 21 (1) WpHG of the following: 1. On September 6, 2010 the percentage of voting rights of BlackRock, Inc. in SAP AG exceeded the threshold of 3% and amounts to 3.59% (44,022,670 voting rights) as per this date. All of the voting rights are to be attributed to BlackRock, Inc. pursuant to section 22 (1) sentence 1 No. 6 in connection with sentence 2 WpHG. 2. On September 6, 2010 the percentage of voting rights of BlackRock Financial Management, Inc. in SAP AG exceeded the threshold of 3% and amounts to 3.46% (42,429,444 voting rights) as per this date. All of the voting rights are to be attributed to BlackRock Financial Management, Inc. pursuant to section 22 (1) sentence 1 No. 6 in connection with sentence 2 WpHG. 3. On September 6, 2010 the percentage of voting rights of BlackRock Holdco 2, Inc. in SAP AG exceeded the threshold of 3% and amounts to 3.46% (42,429,444 voting rights) as per this date. All of the voting rights are to be attributed to BlackRock Holdco 2, Inc. pursuant to section 22 (1) sentence 1 No. 6 in connection with sentence 2 WpHG. 14.09.2010 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: SAP AG Dietmar-Hopp-Allee 16 69190 Walldorf Deutschland Internet: www.sap.com End of Announcement DGAP News-Service

GBC im Fokus

Neovacs S.A.: Kurzfristige Potenziale durch Fast-Track-Zulassung möglich

Das in Frankreich ansässige Biotechnologieunternehmen Neovacs S.A. fokussiert sich auf die Entwicklung so genannter Kinoide, welche für die Behandlung von Autoimmunerkrankungen sowie entzündlichen Erkrankungen verwendet werden. Der Neovacs-Wirkstoff wird derzeit im Rahmen einer klinischen Studie IIb (SLE) in 19 Ländern (Europa, Asien, Lateinamerika, USA) an 178 Patienten untersucht. Wir rechnen mit den ersten Ergebnissen in Sommer 2017. Im Rahmen des DCF-Bewertungsmodells haben wir inkl. eines hohen Sicherheitsabschlages einen fairen Wert von2,90 € je Aktie ermittelt. Wir vergeben das Rating KAUFEN.

Aktueller Webcast

Mobimo Holding AG

Presentation of the interim results 2016

04. August 2016

Aktuelle Research-Studie

MOLOGEN AG

Original-Research: Mologen AG (von First Berlin Equity Research GmbH): BUY

22. Juli 2016